Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B.
about
Salvianolic acid B prevents epithelial-to-mesenchymal transition through the TGF-beta1 signal transduction pathway in vivo and in vitroPharmacological actions and therapeutic applications of Salvia miltiorrhiza depside salt and its active componentsHerbal traditional Chinese medicine and its evidence base in gastrointestinal disordersSalvianolic acid B reverses the epithelial-to-mesenchymal transition of HK-2 cells that is induced by transforming growth factor-βLiver fibrosis and protection mechanisms action of medicinal plants targeting apoptosis of hepatocytes and hepatic stellate cellsEvolving therapies for liver fibrosis.A solid-phase extraction method for high-performance liquid chromatographic determination of salvianolic acid B in rabbit plasma: application to pharmacokinetic study.Biological analysis of herbal medicines used for the treatment of liver diseases.Salvianolic Acid B Inhibits ERK and p38 MAPK Signaling in TGF-β1-Stimulated Human Hepatic Stellate Cell Line (LX-2) via Distinct PathwaysChinese medicines as a resource for liver fibrosis treatmentExperimental study of effect of Ganyanping on fibrosis in rat livers.Salvianolic acid B-induced microRNA-152 inhibits liver fibrosis by attenuating DNMT1-mediated Patched1 methylation.Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease.Salvianolic Acid B reducing portal hypertension depends on macrophages in isolated portal perfused rat livers with chronic hepatitis.Salvianolic Acid B Attenuates Rat Hepatic Fibrosis via Downregulating Angiotensin II SignalingSequential changes of serum ferritin levels and their clinical significance in lamivudine-treated patients with chronic viral hepatitis BMicroRNA-17-5p-activated Wnt/β-catenin pathway contributes to the progression of liver fibrosis.Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation.Salvianolic Acid B Attenuates Experimental Pulmonary Fibrosis through Inhibition of the TGF-β Signaling Pathway.Effect of Fuzheng Huayu formula and its actions against liver fibrosis.Pay attention to the study on active antiliver fibrosis components of Chinese herbal medicine.Fuzheng huayu capsule in the treatment of liver fibrosis: clinical evidence and mechanism of action.Pathogenesis of liver cirrhosis.Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis.Antifibrotic therapies in the liver.A comprehensive overview of hepatoprotective natural compounds: mechanism of action and clinical perspectives.Salvianolic acid B inhibits mitochondrial dysfunction by up-regulating mortalin.Novel anti-infective potential of salvianolic acid B against human serious pathogen Neisseria meningitidis.Quercetin Remodels the Tumor Microenvironment To Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles.The inhibitory effect of salvianolic acid B on TGF-β1-induced proliferation and differentiation in lung fibroblasts.Salvianolic acid B attenuates hepatocyte apoptosis by regulating mediators in death receptor and mitochondrial pathways.Down-regulation of CD40 gene expression and inhibition of apoptosis with Danshensu in endothelial cells.SALVIANOLIC ACID B ALLEVIATING MYOCARDIUM INJURY IN ISCHEMIA REPERFUSION RATS.Expression of RNase H of human hepatitis B virus polymerase in Escherichia coli.Ginkgo biloba extract reverses CCl4-induced liver fibrosis in ratsTargeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy.Effect of compound rhodiola sachalinensis A Bor on CCl4-induced liver fibrosis in rats and its probable molecular mechanisms.Salvianolic acid B inhibits low-density lipoprotein oxidation and neointimal hyperplasia in endothelium-denuded hypercholesterolaemic rabbits.Liquid chromatography mass spectrometry for the determination of salvianolic acid B, a natural compound from the herb Danshen in rat plasma and application to pharmacokinetic study.Drugs and Targets in Fibrosis.
P2860
Q21284189-5CF213A1-97FC-4A78-AF0E-107334A6D72BQ26825621-1D3C3E6F-F5CB-4E22-9C65-B8E287581060Q26992265-5BC6ED52-4665-443C-8437-ECC0CCC1679BQ28236906-4CF27F5C-A0F1-4273-B12E-3A9CBBBB59CFQ30369750-3FEB5C17-0DC9-4D8D-98B8-2519A34F81C5Q30539166-0790C543-C302-416D-8AA9-E8B95E01BFE1Q33269113-059882D1-8F5F-411F-9614-9A7F85CE9A51Q33785052-80810A53-9F0B-4DB7-987F-E47119DC4631Q35163498-B41711B9-7D6F-4292-9DB7-8B26B5E2A559Q35575460-E76205F2-D094-431F-AEE8-0876CC64231BQ36179847-253B682C-A5EC-4A08-9BAB-E3F119020AE1Q36232847-CBB701FB-2C87-4EB7-8BAE-892D490E445CQ36242106-A59A2D42-5B1A-468A-B8A8-3805F9DA6058Q36345842-45227EEE-0B68-46FF-8DCE-30A97269B530Q36456025-A710954B-7491-4CC9-9673-009B84DFF829Q36474696-B677D4F3-FC94-4A2F-A1C6-525A0021253CQ36729351-B96970A0-CD68-47C0-A3B5-2970147A23CDQ36909491-1FE9E5AB-66CA-4B41-A59C-240D94D2DEFDQ36986125-1305C6D6-2E88-4E3A-9A8E-221BA48BBD4FQ37289563-3FDA59E5-6D55-4D5C-B2A3-06024F1E10B3Q37995976-10E46642-2ED8-42E4-97F4-9805360467B4Q37995977-B36A96F9-B1F1-4E5D-9C65-1E8AB795FA84Q38223369-5B37E451-6A43-41D9-9418-8530B40F8411Q38326327-4551E3F2-A563-4ABF-847B-4B0ACE4AA96BQ38480164-9A0AC7DD-E899-4439-82F7-4A9A703EF66CQ38588143-444FA5C1-F19B-440A-84C6-7227F3CC82A8Q38714228-4CADE031-63D9-457F-A18F-D9E9B0408BCAQ38804347-82D07A69-5B15-4EDF-9E87-84F2399A00B9Q38834366-2C57A59E-4192-4EA9-8A5C-92C5C2BCECE6Q39011632-C7759462-84ED-40D0-B26D-6EE4793C1EECQ39704562-C3217CCB-5374-44FF-B6B4-EAF34B41889CQ39907191-1841A3C3-D2E7-4C54-B942-A4D1F6C768EDQ41481781-EA3FB163-FD7B-46B5-87ED-CF151E909473Q41813550-E04A4EC6-E7BA-4610-8629-84B17714084CQ42123715-3EC17093-DDA4-4ED0-A423-BA8030109D5DQ42591676-B121E2C8-66C6-4729-9D70-610D0F1922C7Q43206635-CAEBB4D5-FF24-4D94-B75A-EF89A14249BEQ45855162-89CCE6C4-61E2-4472-AC0D-47AF840216D2Q46010811-7E8BD992-30BF-48BE-9512-7D441A362558Q47119118-52336197-7A2F-4089-A4CC-8C04C0572027
P2860
Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Clinical observation of salvia ...... brosis in chronic hepatitis B.
@ast
Clinical observation of salvia ...... brosis in chronic hepatitis B.
@en
type
label
Clinical observation of salvia ...... brosis in chronic hepatitis B.
@ast
Clinical observation of salvia ...... brosis in chronic hepatitis B.
@en
prefLabel
Clinical observation of salvia ...... brosis in chronic hepatitis B.
@ast
Clinical observation of salvia ...... brosis in chronic hepatitis B.
@en
P2093
P2860
P356
P1476
Clinical observation of salvia ...... brosis in chronic hepatitis B.
@en
P2093
Cheng-Hai Liu
Da-Yuan Zhu
Hong-Tu Gu
Hui-Ming Xue
Lie-Ming Xu
Yi-Yang Hu
Zhi-Qiang Xu
Zhi-Qing Zhang
P2860
P304
P356
10.3748/WJG.V8.I4.679
P407
P577
2002-08-01T00:00:00Z